Plaque Psoriasis

Neal Bhatia, MD, FAAD, provides an overview of the efficacy and safety results of the DERMIS 1 and DERMIS 2 trials for chronic plaque psoriasis treatment.

Neal Bhatia, MD, FAAD, discusses the current treatment landscape for patients with chronic plaque psoriasis, focusing specifically on PDE4 inhibitors.

Dermatology experts discuss the rapid expansion of the treatment armamentarium of plaque psoriasis and how has it shifted treatment approaches to plaque psoriasis.

Brad Glick, DO, AOCD, leads a discussion about the current therapeutic landscape and approval of various biologics therapies for the management plaque psoriasis.

This newly-approved monoclonal antibody was developed as a citrate-free formulation of adalimumab.

New research into bimekizumab for psoriatic arthritis suggests the treatment to be effective for joint and skin improvements at 16 weeks.

Darren West, MPAS, PA-C, and Douglas DiRuggiero, DMSc, PA-C, talk about how the treatment of plaque psoriasis has changed as understanding of the disease grows.

Experts in dermatology discuss how clinician understanding of plaque psoriasis has evolved over time.

This year saw 4 new FDA approvals for the chronic condition. But dermatologists are still not satisfied.

Leon Kircik, MD, shares his impressions of the long-term data of roflumilast, and where it fits into clinical practice.

Leon Kircik, MD, reviews a recent study of roflumilast and its long-term efficacy and safety data in chronic plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, comments on the need for multidisciplinary care providers in light of comorbidities in plaque psoriasis.

Douglas DiRuggiero, DMSc, PA-C, reviews the role of nurse practitioners, physician assistants, and pharmacists in managing plaque psoriasis.

New research highlights the growing number of claims among all providers, including advanced practice practitioners and non-dermatologists, of Cal/BD foam usage for Medicare beneficiaries.

A discussion with Emily Strouphauer on her team's findings regarding mental health in pediatric psoriasis, as well as her views on helping younger patients facing these issues.

In her HCPLive interview, Emily Strouphauer, BSA, spoke about her team’s recent findings on the association between pediatric psoriasis and anxiety and depression.

In an interview with HCPLive, Dr. Chovatiya spoke about recent FDA approvals for psoriasis treatments, including deucravacitinib, spesolimab, roflumilast, and tapinarof.

During his HCPLive interview, Dr. Eichenfield described the results from the phase 3 TRuE-AD trials testing ruxolitinib for atopic dermatitis, including how the findings might affect treatment for vitiligo or psoriasis.

Leon Kircik, MD, discusses the recent FDA approval of roflumilast for plaque psoriasis treatment.

Leon Kircik, MD, provides an overview of PDE4 inhibitors in the treatment of plaque psoriasis.

In a segment from his HCPLive interview, Dr. Lal described the difference between the skin microbiome and the gut microbiome, and their effects on psoriasis.

In an interview segment on HCPLive, Dr. Lal described several treatments approved in 2022 for psoriasis patients such as spesolimab, roflumilast, and tapinarof.

At week 16, the static Physician’s Global Assessment scores were significantly greater in the mirikizumab group than in the placebo group.

Pediatric care requires understanding, not only of the disease impact, but also its presentation and management in children.

In a recent study, patients with psoriasis and coexistent lupus erythematosus were analyzed regarding their clinical characteristics, condition management, and quality of life.